Available online at www.sciencedirect.com
Acta Biomaterialia 5 (2009) 1035–1045
www.elsevier.com/locate/actabiomat
Preparation and characterization of starch-poly-e-caprolactone
microparticles incorporating bioactive agents for drug delivery
and tissue engineering applications
E.R. Balmayor a,b,*, K. Tuzlakoglu a,b, H.S. Azevedo a,b, R.L. Reis a,b
a
3B’s Research Group – Biomaterials, Biodegradables and Biomimetics, Department of Polymer Engineering, University of Minho,
Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Zona Industrial da Gandra,
S. Cláudio do Barco, 4806-909 Caldas das Taipas, Guimarães, Portugal
b
IBB – Institute for Biotechnology and Bioengineering, PT Government Associated Laboratory, Braga, Portugal
Received 11 July 2008; received in revised form 2 October 2008; accepted 13 November 2008
Available online 3 December 2008
Abstract
One limitation associated with the delivery of bioactive agents concerns the short half-life of these molecules when administered intravenously, which results in their loss from the desired site. Incorporation of bioactive agents into depot vehicles provides a means to
increase their persistence at the disease site. Major issues are involved in the development of a proper carrier system able to deliver
the correct drug, at the desired dose, place and time. In this work, starch-poly-e-caprolactone (SPCL) microparticles were developed
for use in drug delivery and tissue engineering (TE) applications. SPCL microparticles were prepared by using an emulsion solvent
extraction/evaporation technique, which was demonstrated to be a successful procedure to obtain particles with a spherical shape (particle size between 5 and 900 lm) and exhibiting different surface morphologies. Their chemical structure was confirmed by Fourier transform infrared spectroscopy. To evaluate the potential of the developed microparticles as a drug delivery system, dexamethasone (DEX)
was used as model drug. DEX, a well-known component of osteogenic differentiation media, was entrapped into SPCL microparticles at
different percentages up to 93%. The encapsulation efficiency was found to be dependent on the polymer concentration and drug-to-polymer ratio. The initial DEX release seems to be governed mainly by diffusion, and it is expected that the remaining DEX will be released
when the polymeric matrix starts to degrade. In this work it was demonstrated that SPCL microparticles containing DEX can be successfully prepared and that these microparticular systems seem to be quite promising for controlled release applications, namely as carriers of important differentiation agents in TE.
! 2008 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Keywords: Poly-e-caprolactone; Starch-based microparticles; Emulsion-solvent evaporation; Drug delivery; Dexamethasone
1. Introduction
Materials of natural origin have been studied and proposed for a wide range of biomedical applications [1–4].
*
Corresponding author. Address: 3B’s Research Group – Biomaterials,
Biodegradables and Biomimetics, Department of Polymer Engineering,
University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Zona
Industrial da Gandra, S. Cláudio do Barco, 4806-909 Caldas das Taipas,
Guimarães, Portugal. Tel.: +351 253 510900; fax: +351 253 510909.
E-mail address: erosado@dep.uminho.pt (E.R. Balmayor).
Materials such as collagen, alginate, hyaluronic acid, silk
fibroin, chitosan and starch are among the most studied
polymers with numerous advantages depending on the specific applications [5–13]. One of the most relevant benefits
of using materials of natural origin is their biodegradability
inside the human body. Biodegradable systems have the
ability to function satisfactorily for a certain time and subsequently to degrade into products easily cleared from the
body, with no need for surgery for their removal. This is a
particularly desirable property for the design of carriers for
the controlled delivery of therapeutic drugs, since it will
permit the entrapped drug to be released slowly, allowing
1742-7061/$ - see front matter ! 2008 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.actbio.2008.11.006
1036
E.R. Balmayor et al. / Acta Biomaterialia 5 (2009) 1035–1045
repeating dosages and ensuring the successful effect of the
treatments [14] as the polymer carrier degrades.
Starch-based polymers have been studied and proposed
in the last decade by Reis and coworkers [13,15–21] for several biomedical applications, such as drug delivery carrier
systems, hydrogels and partially degradable bone cements,
materials for bone replacement/fixation or fillers for bone
defects, and porous structures to be used as scaffolds in tissue engineering of bone and cartilage. These materials were
found to be biocompatible [16,22–23], noncytotoxic, biodegradable [24–27] and have shown a great processing
versatility [13]. These blended materials have potential
application as carriers for the controlled release of different
bioactive agents in the form of microparticular systems.
Indeed, biodegradable starch-based microparticles have
been widely investigated and proposed as drug delivery systems [28–30]. For instance, starch microparticles using soluble potato starch have been developed and proposed for
the release of a nonsteroidal anti-inflammatory drug [21].
Moreover, a blend of starch and polylactic acid have been
used for the encapsulation of steroids, growth factors and
bioactive glass in a microparticle system [31–33]. These
studies showed that the starch–polylactic acid microparticles are suitable carriers for the controlled release of bioactive agents for bone tissue engineering applications. In
addition, derivatives of starch, such as starch acetate or
poly(acryl starch), have been described for the incorporation and release of peptides and proteins [34–36]. However,
to our knowledge there has so far been no report in the literature on the development of microparticle systems based
on starch–polycaprolactone blended materials. The combination of a hydrophilic natural material (starch) with a
hydrophobic synthetic polymer (polycaprolactone), both
biodegradable and biocompatible, in a single blended
material constitutes the major advantage of these
microparticles.
Numerous controlled release systems have been developed, ranging from implants [37,38] to novel osmotically
driven pills [38]. The use of noninvasive delivery methods,
such as injectable systems in the form of nano and microparticles, will bring substantial benefits when compared
with some surgical techniques. It has already been reported
that injectable systems made of nano and microparticles
could be applied as carriers of different drugs and bioactive
agents within the field of tissue engineering (e.g. differentiation agents and growth factors [39,40]). Dexamethasone
(DEX) has been widely used in clinical applications to treat
immuno-disorders [41,42], but a more specific and common
use has been the control of the inflammatory response and
tissue repair during organ transplantation [43]. In the last
years, the use of this corticosteroid as an osteogenic agent
has increased considerably in in vitro cell culture to induce
the differentiation of stem cells into an osteoblastic lineage
[41,44–46].
This study aims to establish experimental conditions for
the production of a biodegradable and biocompatible
microparticular system with different characteristics (e.g.
size, size distribution, surface morphology) that can be
used as a potential carrier for the delivery of important bioactive agents. For that, we have used a polymeric blend of
starch with polycaprolactone. The microparticular system
was characterized in terms of particle size, size distribution,
surface morphology and chemical structure. The carrier
potential was evaluated by encapsulating DEX into the
microparticles and its release behavior studied in vitro.
2. Materials and methods
2.1. Materials
A polymeric blend of corn starch with poly-e-caprolactone (SPCL, 30–70 wt.%) was used in this study. More
details about the thermal properties of this polymeric blend
can be found elsewhere [47]. Methylene chloride and polyvinyl alcohol (PVA) were obtained from Sigma, and used as
received. Unless otherwise indicated, the molecular weight
(MW) of the PVA used was in the range 30,000–70,000 g
mol!1 DEX (97%, cell culture tested, Sigma) was used as a
bioactive molecule for the encapsulation studies. Solvents
for high-performance liquid chromatography (HPLC) (acetonitrile and water) were HPLC grade (LABSCAN). Triamcinolone was used as internal standard for DEX
quantification. Potassium bromide (KBr) for IR spectroscopy (P99.5%) was obtained from Sigma. Other chemicals
were of reagent grade, all from Sigma, and used as received.
2.2. Preparation of SPCL microparticles
SPCL microparticles were prepared by using an emulsion solvent extraction/evaporation technique [48]. Briefly,
SPCL was dissolved in 5 ml of methylene chloride under
vigorous stirring. This solution was dropped into a
200 ml PVA solution, and emulsified for 4 h at different
stirring rates. Different experimental conditions were evaluated, and the details of each condition are summarized in
Table 1. The microparticles where then collected by filtration, washed with distilled water and vacuum dried in a
desiccator. For the selected condition to be loaded with
DEX, SPCL was mixed with the steroid at different percentages (5, 10 and 15% (w/w), relatively to polymer
weight) and dissolved in methylene chloride. The same procedure was performed as described for unloaded microparticles. The reaction medium was stored at 4 "C for later
quantification of unloaded DEX. All experiments were carried out in triplicate.
2.3. Physicochemical characterization of SPCL
microparticles
2.3.1. Morphological analysis: scanning electron microscopy
(SEM) and micro-computed tomography (l-CT)
To analyze the morphology and surface of the microparticles obtained under the different experimental conditions,
the samples were mounted onto aluminium stubs with a
1037
E.R. Balmayor et al. / Acta Biomaterialia 5 (2009) 1035–1045
Table 1
Effect of the experimental conditions employed during microparticle production on the size and morphology of the resulting microparticles.
Condition
SPCLa
(%)
Emulsification medium PVAb (%) [MW
(g mol!1)]
Stirring rate
(rpm)
Reaction time
(h)
Particle size
(lm)
Shape/surfacec
(SEM)
I
II
III
IV
V
VI
VII
VIII
IX
X
XI
XII
5
5
10
10
10
10
10
10
10
15
20
10
1
0.5
0.5
1 [30,000–70,000]
1 [70,000–100,000]
1
1
2
5
1
1
1
600
600
600
600
600
800
400
600
600
600
600
20,000
4
4
4
4
4
4
4
4
4
4
4
4
102.3 ± 4.1
200.4 ± 3.7
575.1 ± 4.6
499.6 ± 4.8
702.1 ± 19.0
283.0 ± 21.0
913.7 ± 9.8
376.0 ± 3.2
324.1 ± 15.3
770.0 ± 8.7
810.0 ± 16.2
5.73 ± 8.19
s/s
s/s
r/p
r/p(HP)
r/p(HPD)
r/p(HPD)
r/p(HPD)
r/p
r/p(HPD)
r/p
r/p(HPD)
s/s
a
b
c
SPCL, polymeric blend of corn starch with poly-e-caprolactone.
PVA, polyvinyl alcohol.
s/s, spherical/smooth; r/p, round/porous; HPD, high polydispersity; HP, highly porous.
carbon tape and gold sputter-coated (Fisons Instruments,
Sputter Coater SC502, UK). All images were collected with
a Leica Cambridge S-360 model (Cambridge, UK) scanning electron microscope.
Microparticle samples with porous surfaces (experimental condition III, see Table 1 for details) were
scanned by micro-computed tomography (l-CT) using
a l-CT 20 equipment (SCANCO Medicals, Switzerland).
The energy of the scanner used was 100 kv/98 lA intensity. A threshold range of values of 141–255 was used to
estimate the porosity of the samples. Approximately 40
slices of the sample were obtained. Mimics (Materialise,
Belgium), CT Analyser and CT Vol Realistic 3D Visualization (SkyScan, Belgium) software were used for image
processing and to create and visualize the three-dimensional representation.
2.3.2. Size distribution
To determine the size distribution of the microparticles
obtained under the different experimental conditions, the
microparticles were separated through a series of standard
sieves (20, 60, 100, 125, 150, 250, 450, 500, 650, 900 and
1000 lm; Linker Industrie-Technik, Germany). The microparticle fraction that passed through a sieve and was
retained on the sieve with a certain pore size was collected
and weighed, and finally correlated with the total mass of
the microparticle sample analyzed.
2.3.3. Fourier transform infrared (FTIR) spectroscopy
The chemical structure of the microparticles (unloaded,
loaded with DEX and after release) was analyzed by FTIR
(IRPrestige-21 FRIT-8400S, Shimadzu, Japan) in transmission mode. For that, microparticles (1 mg) were mixed
with KBr (40 mg) and then formed into a disc in a manual
press (161–1100 hand press, Pike Technologies, Madison,
WI). Transmission spectra were recorded using at least 32
scans with 4 cm!1 resolution, in the spectral range 4000–
600 cm!1.
2.3.4. X-ray diffraction (XRD)
In order to confirm the encapsulation and release of
DEX into and from the SPCL microparticles, and to access
the physical state of the entrapped drug, X-ray diffraction
patterns of DEX and SPCL microparticles (unloaded,
loaded with DEX and after the release studies) were
obtained in a X-ray diffractometer (X’Pert MPD, Philips,
The Netherlands). The data collection was performed with
a Cu anode and monochromator used at a voltage of
40 kV. The samples were analyzed over the angle range
(2h) 2"–60".
2.4. Determination of DEX encapsulation efficiency and
release profile from SPCL microparticles
2.4.1. Encapsulation efficiency
The encapsulation efficiency of DEX into the SPCL
microparticles was calculated using the following equation:
% Encapsulation eff" ¼ ½ðC i ! C r Þ=C i ' ( 100;
ð1Þ
where Ci is the initial concentration of DEX added, and Cr
is the concentration of unloaded DEX (remaining in the
reaction medium: PVA solution where loaded microparticles were produced). DEX concentration was determined
by HPLC (see Section 2.5). Determinations were made in
triplicate and the average is reported.
2.4.2. In vitro release of DEX from SPLC microparticles
Pre-weighed SPCL–DEX-loaded microparticles were
suspended in 40 ml of PBS (pH 7.4, 0.01 M) at a concentration of 2.5 mg ml!1. The microparticles were maintained at
37 "C under constant agitation (50 rpm) for 30 days in a
shaking bath. At predetermined time points, first each
30 min, then each 1 and 2 h, and 4, 5, 7, 10, 14, 30 days,
1038
E.R. Balmayor et al. / Acta Biomaterialia 5 (2009) 1035–1045
1 ml aliquots of the supernatant were taken and replaced
with the same volume of fresh PBS solution. DEX concentration was quantified by HPLC. All the release experiments were carried out in triplicate and the average is
reported.
2.5. Quantification of DEX by HPLC
Before HPLC analysis, samples from the reaction medium were extracted three times with a mixture of hexane
and ethyl acetate in the same proportions. The final extract
was collected and the solvent allowed to evaporate under
nitrogen flow. The dry extract was reconstituted in a mixture of acetonitrile/water (50:50 v/v, mobile phase) before
analysis. The aliquots from the release medium (PBS solution containing released DEX) were analyzed directly as
taken.
DEX was quantified by reverse-phase (RP) HPLC.
HPLC was performed on a Jasco PU-2080 Plus system
using a RP-18 column (LiChrospher, 5 lm, Merck, Germany) with acetonitrile/water (50:50 v/v) as mobile phase
at a flow rate of 0.5 ml min!1. Absorbance was monitored at 254 nm (UV detector Jasco 870-UV). The column was eluted in isocratic conditions over 20 min.
Data acquisition and peak areas were determined with
a Shimadzu C-R6A Chromatopac software. The concentration of DEX was calculated by using a calibration
curve (y = 8697.18 + (1.65 ( 107)x, R2 = 0.9995). Triamcinolone was used as internal standard.
3. Results and discussion
3.1. Preparation of SPCL microparticles: evaluation of the
effect of different experimental conditions on particle size and
morphology
In order to optimize the proposed methodology for the
production of SPCL microparticles with different morphological characteristics and sizes, several experimental conditions were tested (summarized in Table 1).
Four different polymeric (SPCL) concentrations were
studied to investigate the effect of this parameter on the size
and morphology of the microparticles. Fig. 1 shows the
morphological characteristics of the SPCL microparticles
obtained with different polymeric concentrations.
The viscosity of the SPCL solution is directly related to
the polymeric concentration [49]. Consequently, at higher
concentrations of SPCL, there is a rather significant
increase in the viscosity of the solution and, as result, the
size of the drops in the emulsification medium is higher,
which leads to an increase the microparticle size (experimental conditions I, IV, X, XI: see Table 1). It was found
that at polymer concentrations higher than 10% the polydispersity increases due to the higher particle size obtained
under these conditions. It was also observed that at higher
polymeric concentrations, the microparticles exhibit a porous surface, as shown in Fig. 2b and c, when compared
with the smooth morphology of the microparticles
obtained at lower polymer concentrations (Fig. 2a). A representative sample (experimental condition IV, Table 1)
Fig. 1. SEM micrographs of SPCL microparticles obtained under different experimental conditions: (a and b) Condition I–SPCL 5%; (c and d) condition
IV–SPCL 10% (see Table 1 for details).
E.R. Balmayor et al. / Acta Biomaterialia 5 (2009) 1035–1045
1039
the microparticles slightly decreases as the PVA concentration increases (experimental conditions III, IV, VIII, IX:
see Table 1), but this effect was not as significant as the
one observed for the polymer concentration. The spherical
shape of the microparticles is lost as the concentration of
PVA becomes higher than 2%, and the surface of the
microparticles becomes more porous. Analyzing the effect
of PVA molecular weight (MW), it was found a noticeable
increase in the size of the microparticles (experimental conditions IV, V: see Table 1), when the PVA MW range
increased from 30,000–70,000 to 70,000–100,000 g mol!1.
Therefore, a concentration of 0.5 and 1% PVA with a
MW range 30,000–70,000 g mol!1 was selected as optimum, avoiding loss of spherical shapes, deformation of
particles and uncontrolled particle size.
One of the most important factors affecting the microparticle size is the stirring speed during their preparation
[50]. It has been already shown in the literature [51] that
by varying the stirring speed from hundreds to thousands
of rpm, micro to nanoparticles can be produced. In our
experiments, we observed that by increasing the stirring
rate, the size of the microparticles drastically decreased
(experimental conditions VII (400 rpm), IV (600 rpm), VI
(800 rpm) and XII (20,000 rpm) in Table 1). In fact, an
increase in the stirring speeds provides higher energy to disperse two immiscible phases (oil in water phase) and form
the emulsion, producing smaller drops of oil phase in the
water (because it is breaking the oil phase into smaller
drops) and as a result smaller particles are obtained.
Fig. 5 shows the morphological characteristics and the size
of the SPCL microparticles obtained with higher stirring
speeds.
3.2. Physicochemical characterization of unloaded SPCL
microparticles
Fig. 2. SEM micrographs of the surface of SPCL microparticles showing
different morphologies when using different polymer concentrations: (a)
Condition I–SPCL 5%; (b) condition IV–SPCL 10%; (c) condition XI–
SPCL 20% (see Table 1 for details).
from porous microparticles was analyzed by micro-CT
scan (Fig. 3). As result, 44% porosity was obtained, which
indicated that 10% of polymer concentration is adequate
for the production of microparticles with a porous
structure.
By means of selecting the polymer concentration in the
range of 5–10%, it is possible to obtain microparticles with
a desired size range (100–600 lm), a narrow size distribution as illustrated in Fig. 4, and different surface
morphologies.
The effect of the reaction medium composition was also
studied, by the varying the concentration of PVA in the
emulsification medium from 0.5 to 5%. The use of PVA
as an emulsion stabilizer results in a quite successful preparation of SPCL microparticles. By analyzing the results
presented in Table 1, it can be observed that the size of
Iodine–potassium solution (Lugol) is a well-known and
useful solution for chemically identifying the presence of
starch molecules [31]. The amylose present in the starch
molecule has a helical secondary structure [52], where substances such as iodine can lodge, forming a complex as an
inclusion compound. This starch–iodine forms a coloured
complex (dark blue), and this property can be used to identify the presence and distribution of starch in complex
polymeric blends. Staining with Lugol solution was performed for all experimental conditions. These experiments
revealed the presence of starch in the microparticles, since a
dark blue staining was observed in all conditions. A more
intense staining was observed in the microparticles with a
porous surface. This may due to the diffusion of iodine to
the interior of the microparticles in this case, while in the
microparticles with smooth surface the iodine is mainly
reacting with the starch molecules present at the surface
of the microparticles.
The infrared spectrum of SPCL microparticles exhibits
the same characteristic peaks of the raw material before
processing (the infrared spectrum of SPCL raw material
1040
E.R. Balmayor et al. / Acta Biomaterialia 5 (2009) 1035–1045
Fig. 3. Micro-CT three-dimensional reconstruction of the SPCL microparticle illustrating the porosity of the obtained particulate structure (experimental
condition IV: see Table 1).
100
X Axis legend
y=y0 + (A/(w*sqrt(PI/2)))*exp(-2*((x-xc)/w)^2)
Percent of total weight (%)
Adj. R-Square
1: + 500 µm
2: 500-450 µm
3: 450-250 µm
4: 250-150 µm
5: 150-125 µm
6: 125-100 µm
7: 100-60 µm
8: 60-20 µm
9: - 20 µm
80
60
40
Value
1.86578
5.99685
0.88333
73.4708
0.44167
1.04004
66.3638
y0
xc
w
A
sigma
FWHM
Height
0.88166
Standard Error
1.41356
0.16544
0.15421
15.172
20
0
0
1
2
3
4
5
6
7
8
9
10
Porous size of the standard sieves (µ m)
Fig. 4. Size distribution of the SPCL microparticles (experimental condition I: see Table 1).
Fig. 5. SEM micrographs of SPCL microparticles obtained at higher stirring speed, at (a) lower and (b) higher magnification. Condition XII–20,000 rpm,
resulting in a stronger decrease in the size of the resulting microparticles.
E.R. Balmayor et al. / Acta Biomaterialia 5 (2009) 1035–1045
Table 2
Characteristic IR bands of the microparticle components (starch and
polycaprolactone) [12,27].
cm!1
Vibration
Abbreviation
2944/2864
(from PCL) Asymmetric/
symmetric CH2 stretching
C@O stretching
Asymmetric COC stretching
OCAC stretching/symmetric
COC stretching
(from starch) OH stretching
CAOAC glycosidic bond
tas(CH2), ts(CH2)
1724
1244
1195
3362
1021/1048
t(C@O)
tas(COC)
t(OCAO), ts(COC)
t(OH)
t(COC)
has been described in previous publications [25,53–55]).
The bands from PCL and starch were easily identified.
The strongest bands and their assignments are summarized
in Table 2. This demonstrates that both components of the
blend remained present in the chemical structure of the
obtained microparticles.
3.3. Determination of DEX encapsulation efficiency and
in vitro release profile
For the loading of DEX and in vitro release experiments, conditions I–IV (Table 1) were selected for the preparation of SPCL microparticles. Using these conditions,
DEX-loaded microparticles were successfully produced.
The obtained microparticles exhibited a morphology very
Fig. 6. SEM micrographs of SPCL–DEX-loaded microparticles (experimental condition IV: see Table 3).
Table 3
Effect of the initial amount of DEX on its encapsulation efficiency in the
SPCL microparticles.
Condition
% SPCL
Particle size
(lm)
Drug/polymer
ratio (w/w)
Loading
efficiency (%)
IV-DEX
10
525.3 ± 7.9
1:20
1:10
1:5
74.99
90.72
93.65
1041
similar to unloaded microparticles (see Figs. 1d and 6 for
morphological comparison). A more compact surface was
found and the particle size slightly increased as result of
DEX entrapment. The quantification of the DEX, before
and after loading, was performed by HPLC.
3.3.1. Encapsulation efficiency
For the determination of the encapsulation efficiency,
the amount of DEX remaining in the reaction medium
(unloaded DEX) was quantified. Table 3 shows the encapsulation efficiency values as a function of the initial amount
of DEX added to the polymer solution. Higher values were
obtained when 15% of DEX was added. There is a notable
increase in the encapsulation efficiency when there is an
increment from 5 to 10% in the initial DEX amount. However, increasing the initial amount of DEX higher than 10%
yielded no significant increase in encapsulation efficiency.
Taking these results into account, 15% was used as the initial amount of DEX (1:5 drug/polymer ratio) for the
release studies.
3.3.2. In vitro release of DEX from SPLC microparticles
Drug release from a polymeric matrix is controlled by a
variety of factors, such as the solubility of the drug within
the surrounding fluid, the size of the drug molecule and its
mobility within the swollen polymeric network, and the dissolution rate of the polymer and polymer–drug interactions. Moreover, several authors have reported that the
release kinetic is dependent on different characteristics of
the microparticles (e.g. type of polymer, particle size and
size distribution, surface morphology) [56–61], and these
features can be controlled by the fabrication conditions.
A number of studies in the literature have investigated
the effect of fabrication conditions (e.g. interconnected
pores and channels, emulsification medium concentration
and polymer concentration) on the morphology of
obtained microparticles, drug distribution and release
kinetics [56–58,60,61]. Thus, understanding the influence
of microparticle characteristics on the release behavior is
important for yielding useful products that can meet different clinical applications.
The release profiles of DEX from SPCL microparticles
during 30 days in PBS are illustrated in Fig. 7. The release
in the first day is shown in more detail in the insert. The initial burst release is attributable to the release of the drug
that is present at the outermost layer of the microparticles
and is released quickly [4,27,62–63]. The burst release is
then followed by a sustained release stage, which is most
likely due to the hydrophobic character of poly(caprolactone) (PCL) polymer present in the microparticles and consequently its corresponding low permeability to water. The
hydrophobicity of PCL (70% in the blend) can cause a
delay in water penetration and, consequently, the diffusion
of the drug through the polymeric matrix into the aqueous
release medium was retarded. On the other hand, it is necessary to take in consideration that the biodegradation of
SPCL in PBS medium is slow [25] when compared with
1042
E.R. Balmayor et al. / Acta Biomaterialia 5 (2009) 1035–1045
60
Condition IV-SPCL10%
Condition I -SPCL 5%
40
25
Cumulative DEX release (%)
Cumulative DEX release (%)
50
30
20
10
20
15
10
5
0
0
2
4
6
8
10
12
time (hours)
0
0
100
200
300
time (hours)
400
500
600
Fig. 7. In vitro release profiles of DEX from SPCL microparticles in PBS (pH 7.4, 0.1 M), at 37 "C and 50 rpm, for a period of 4 weeks. DEX-loaded
SPCL microparticles obtained by the use of different polymer concentrations are compared. The insert graph shows the DEX release for a period of 11 h.
other biodegradable polymers. Therefore, at the initial
stages, the release of DEX from the SPCL microparticles
is mainly controlled by diffusion mechanisms, and it is
expected that the remaining drug in the polymeric matrix
will be released as the degradation process becomes more
significant.
When using higher polymer concentrations in the preparation of the microparticles (Fig. 7a and b) the drug
release profile shows a more sustained pattern. This may
be due to the fact that as the SPCL concentration increases,
the particle size also increases, leading to a decrease in the
total surface area of the microparticle system, reducing the
area that is in direct contact with the water.
Further evidence of the loading and release of DEX
from the SPCL microparticles was shown by FTIR analysis
(Fig. 8). The FTIR spectrum of DEX-loaded SPCL micro-
(d)
(c)
*
*
(b)
*
*
*
*
(a)
*
*
4000
3500
3000
2500
2000
1500
*
1000
1/cm
Fig. 8. FTIR spectra of DEX and SPCL microparticles: (a) DEX; (b) DEX-loaded microparticles; (c) DEX-loaded microparticles after 30 days of in vitro
release; (d) unloaded SPCL microparticles. The characteristics bands of DEX are marked (*).
1043
E.R. Balmayor et al. / Acta Biomaterialia 5 (2009) 1035–1045
..
..
(d)
(c)
... .
(b)
(a)
0
10
20
30
40
50
60
2θ
Fig. 9. XRD diffractograms of SPCL microparticles: (a) unloaded; (b) loaded with DEX; (c) DEX-loaded microparticles after 30 days of release; (d) DEX.
The characteristics peaks of DEX are marked (j).
particles (Fig. 8b) shows the characteristic bands of DEX,
indicating the successful loading of the drug into the microparticles. After the release studies, it can be observed that
there is a reduction in the intensity of the characteristic
bands of DEX in the IR spectrum (Fig. 8c), due to the partial release of the drug from the microparticles. This result
further indicates that the DEX present at the outermost
layer of the microparticles is released quickly. The release
profile obtained in this study, with an initial burst stage followed by a sustained release (typical of first-order release
kinetic systems), is in accordance with the release behavior
obtained with other delivery systems with similar composition [64].
The structure of the entrapped drug is also an important
aspect to take into consideration in drug delivery systems,
since it is known that transitions from amorphous to crystalline structures may occur. These transitions may affect
the rate of drug release. For this purpose, XRD studies
can show the physical nature of the encapsulated material.
In Fig. 9 XRD diffractograms of DEX, unloaded SPCL
microparticles and SPCL microparticles loaded with
DEX after 30 days of in vitro release are presented. The
XRD pattern of DEX shows several crystalline peaks, as
marked in Fig. 9d. For the DEX-loaded SPCL microparticles it is possible to see the appearance of the characteristic
peaks from the drug at low 2h, between 10" and 20", indicating the crystalline state of the DEX entrapped in the
SPCL matrix. The maintenance of the crystalline structure
may be due to the space available in the polymeric matrix
(e.g. pore formation). Another confirmation of the in vitro
DEX release can be observed in Fig. 9c, where the charac-
teristics peaks of DEX are not observed after 30 days in
PBS.
Several research groups are currently developing controlled release systems in the context of bone tissue engineering with the main goal of inducing in vitro the
osteogenic differentiation of stem cells. A common problem
associated with some of these systems is still in the lack of
control over the drug release. Therefore, in this study we
propose a very attractive drug delivery system, consisting
of SPCL microparticles that can present diverse characteristics depending on the experimental conditions used during processing. The processing method can be adjusted to
obtain particles with different sizes in the micron range,
as well as with distinct surface morphologies from smooth
to porous. Moreover, the developed SPCL microparticles
were found to be biodegradable, noncytotoxic and biocompatible, as reported in a previous study [27]. The in vitro
release studies of DEX, a widely used osteogenic agent,
showed a sustained release pattern for a period of 30 days,
indicating that the developed system might be very useful
for the induction of osteoblastic differentiation of stem
cells.
Further studies will be carried out in order to study the
release behavior of DEX or other bioactive agents in the
presence of enzymes in order to investigate the effect of
matrix degradation on the release kinetics.
4. Conclusions
In this work the production of polymeric microparticles
made from a blend of starch with polycaprolactone (SPCL)
1044
E.R. Balmayor et al. / Acta Biomaterialia 5 (2009) 1035–1045
by means of an emulsion solvent evaporation technique
was evaluated. Microparticles with different morphologies
(smooth and porous) and sizes between 5 and 900 lm could
be obtained by using this methodology. Encapsulation of
DEX into SPCL microparticles was performed with high
encapsulation efficiencies, up to 93%. The in vitro release
studies showed a sustained release pattern for a period of
30 days, indicating the carrier potential of SPCL microparticles for the delivery of important bioactive agents. The
developed systems might be very useful in the in vitro culturing of stem cells aimed at being committed into the
osteoblastic lineage.
Acknowledgments
E.R.B. thanks the Marie Curie Host Fellowships for
Early Stage Research Training (EST) ‘‘Alea Jacta EST”
(MEST-CT-2004-008104) for providing her with a PhD
Fellowship. This work was partially supported by the
European NoE EXPERTISSUES (NMP3-CT-2004500283).
References
[1] Lakshmi SN, Laurencin CT. Biodegradable polymers as biomaterials.
Prog Polym Sci 2007;32(8–9):762–98.
[2] Elvira C, Mano JF, San Román J, Reis RL. Starch-based biodegradable hydrogels with potential biomedical applications as drug
delivery systems. Biomaterials 2002;23(9):1955–66.
[3] Coviello T, Matricardi P, Marianecci C, Alhaique F. Polysaccharide
hydrogels for modified release formulations. J Control Release
2007;119(1):5–24.
[4] Malafaya PB, Silva GA, Reis RL. Natural-origin polymers as carriers
and scaffolds for biomolecules and cell delivery in tissue engineering
applications. Adv Drug Deliv Rev 2007;59(4–5):207–33.
[5] Lacerda De Paoli SH, Ingber B, Rosenzweig N. Structure-release rate
correlation in collagen gels containing fluorescent drug analog.
Biomaterials 2005;26(34):7164–72.
[6] George M, Abraham TE. Polyionic hydrocolloids for the intestinal
delivery of protein drugs: alginate and chitosan – a review. J Control
Release 2006;114(1):1–14.
[7] Price RD, Berry MG, Navsaria HA. Hyaluronic acid: the scientific
and clinical evidence. J Plast Reconstr Aesthet Surg 2007;60:1110–9.
[8] Campoccia D, Doherty P, Radice M, Brun P, Abatangelo G,
Williams DF. Semisynthetic resorbable materials from hyaluronan
esterification. Biomaterials 1998;19(23):2101–27.
[9] MacIntosh AC, Kearns VR, Crawford A, Hatton PV. Skeletal tissue
engineering using silk biomaterials. J Tissue Eng Regen Med
2008;2:71–80.
[10] Altman GH, Diaz F, Jakuba C, Calabro T, Horan RL, Chen J, et al.
Silk-based biomaterials. Biomaterials 2003;24:401–16.
[11] Ko JA, Park HJ, Hwang SJ, Park JB, Lee JS. Preparation and
characterization of chitosan microparticles intended for controlled
drug delivery. Int J Pharm 2002;249:165–74.
[12] Wang LY, Ma GH, Su ZG. Preparation of uniform sized chitosan
microspheres by membrane emulsification technique and application as a carrier of protein drug. J Control Release 2005;106(1–2):
62–75.
[13] Reis RL, Cunha AM. Starch Polymers. In: Buschow KHJ, Cahn RW,
Flemings MC, Ilschner B, Kramer EJ, Mahajan S, Veyssie P, editors.
Encyclopedia of materials: science and technology, vol. 11. New
York: Elsevier Science; 2001. p. 8810–8816.
[14] Thomson RC, Wake MC, Yaszemski MJ, Mikos AG. Biodegradable
polymer scaffolds to regenerate organs. Adv Polym Sci
1995;122:245–74.
[15] Pereira CS, Cunha AM, Reis RL, Vazquez B, San Roman J. New
starch-based thermoplastic hydrogels for use as bone cements or
drug-delivery carriers. J Mater Sci Mater Med 1998;9(12):825–33.
[16] Mendes SC, Reis RL, Bovell YP, Cunha AM, van Blitterswijk CA, de
Bruijn JD. Biocompatibility testing of novel starch-based materials
with potential application in orthopaedic surgery: a preliminary
study. Biomaterials 2001;22(14):2057–64.
[17] Malafaya PB, Elvira C, Gallardo A, San Roman J, Reis RL. Porous
starch-based drug delivery system processed by a microwave route. J
Biomater Sci Polym Ed 2001;12:1227.
[18] Boesel LF, Mano JF, Elvira C, San Roman J, Reis RL. In: Chiellini
E, Solaro R, editors. Biodegradable polymers and plastics. New
York: Kluwer Academic/Plenum Press; 2003. p. 243.
[19] Gomes ME, Sikavitsas VI, Behravesh E, Reis RL, Mikos AG. Effect
of flow perfusion on the osteogenic differentiation of bone marrow
stromal cells cultured on starch based three-dimensional scaffolds. J
Biomed Mater Res A 2003;67:87–95.
[20] Gomes ME, Reis RL. Biodegradable polymers and composites in
biomedical applications: from catgut to tissue engineering. Part I:
Available systems and their properties. Int Mater Rev
2004;49(5):261–73.
[21] Malafaya PB, Stappers F, Reis RL. Starch-based microspheres
produced by emulsion crosslinking with a potential media dependent
responsive behavior to be used as drug delivery carriers. J Mater Sci
Mater Med 2006;17(4):371–7.
[22] Marques AP, Reis RL, Hunt JA. The biocompatibility of novel
starch-based polymers and composites: in vitro studies. Biomaterials
2002;23(6):1471–8.
[23] Gomes ME, Reis RL, Cunha AM, Blitterswijk CA, de Bruijn JD.
Cytocompatibility and response of osteoblastic-like cells to starchbased polymers: effect of several additives and processing conditions.
Biomaterials 2001;22(13):1911–7.
[24] Gomes ME, Godinho JS, Tchalamov D, Cunha AM, Reis RL.
Alternative tissue engineering scaffolds based on starch: processing
methodologies, morphology, degradation and mechanical properties.
Mater Sci Eng C 2002;20(1–2):19–26.
[25] Azevedo HS, Gama FM, Reis RL. In vitro assessment of the
enzymatic degradation of several starch based biomaterials. Biomacromolecules 2003;4(6):1703–12.
[26] Azevedo HS, Reis RL. In: Reis RL, San Roman J, editors.
Biodegradable systems in tissue engineering and regenerative medicine. New York: CRC Press; 2005. p. 178.
[27] Balmayor ER, Tuzlakoglu K, Marques AP, Azevedo HS, Reis RL. A
novel enzymatically-mediated drug delivery carrier for bone tissue
engineering applications: combining biodegradable starch-based
microparticles and differentiation agents. J Mater Sci Mater Med
2008;19:1617–23.
[28] Taguchi T. Chemo-occlusion for the treatment of liver cancer: a new
technique using degradable starch microspheres. Clin Pharmacokinet
1994;26(4):275–91.
[29] Bjork E, Edman P. Characterization of degradable starch microspheres as a nasal delivery system for drugs. Int J Pharm 1990;62(2–
):187–92.
[30] Fahlvik AK, Holtz E, Schroder U, Klaveness J. Magnetic starch
microspheres, biodistribution and biotransformation. A new organspecific contrast agent for magnetic resonance imaging. Invest Radiol
1990;25(7):793–7.
[31] Silva GA, Costa FJ, Neves NM, Coutinho OP, Dias ACP, Reis RL.
Entrapment ability and release profile of corticosteroids from starchbased microparticles. J Biomed Mater Res A 2005;73(2):234–43.
[32] Silva GA, Pedro A, Costa FJ, Neves NM, Coutinho OP, Reis RL.
Soluble starch and composite starch Bioactive Glass 45S5 particles:
synthesis, bioactivity, and interaction with rat bone marrow cells.
Mater Sci Eng 2005;C 25:237–46.
E.R. Balmayor et al. / Acta Biomaterialia 5 (2009) 1035–1045
[33] Silva GA, Coutinho OP, Ducheyne P, Shapiro IM, Reis RL. Starchbased microparticles as vehicles for the delivery of active plateletderived growth factor. Tissue Eng 2007;13(6):1259–68.
[34] Touvinen L, Peltonen S. Drug release from starch-acetate microparticles and films with and without incorporated a-amylase. Biomaterials 2004;25(18):4355–62.
[35] Wikingsson LD, Sjoholm I. Polyacryl starch microparticles as
adjuvants in oral immunization, inducing mucosal and systemis
immune responses in mice. Vaccine 2002;20(27–28):3355–63.
[36] Rydell N, Sjoholm I. Oral vaccination against diphtheria using
polyacryl starch microparticles as adjuvant. Vaccine 2004;22(9–
):1265–74.
[37] Nitsch MJ, Banakar UV. Implantable drug delivery. J Biomater Appl
1994;8(3):247–84.
[38] Langer R, Peppas NA. Advances in biomaterials, drug delivery, and
bionanotechnology. AIChE J 2003;49(12):2990–3006.
[39] Meinel L, Illi OE, Zapf J, Malfanti M, Merkle HP, Gander B.
Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co-glycolide) microspheres. J Control Release 2001;70(1–2):193–202.
[40] Cleland JL, Duenas ET, Park A, Daugherty A, Kahn J, Kowalski J,
et al. Development of poly-(D,L-lactide-co-glycolide) microsphere
formulations containing recombinant human vascular endothelial
growth factor to promote local angiogenesis. J Control Release
2001;72(1–3):13–24.
[41] Connolly AM, Schierbecker J, Renna R, Florence J. High dose
weekly oral prednisone improves strength in boys with Duchenne
muscular dystrophy. Neuromuscul Disord 2002;12(10):917–25.
[42] Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia
LJ, et al. Glucocorticoids suppress bone formation via the osteoclast.
J Clin Invest 2006;116:2152–60.
[43] Galeska I, Kim TK, Patil SD, Bhardwaj U, Chattopadhyay D,
Papadimitrakopoulos F, et al. Controlled release of dexamethasone
from PLGA microspheres embedded within polyacid-containing PVA
hydrogels. AAPS J 2005;7(1):22.
[44] Silva GA, Coutinho OP, Ducheyne P, Reis RL. Materials in
particulate form for tissue engineering. 2. Applications in bone. J
Tissue Eng Regen Med 2007;1(2):97–109.
[45] De Girolamo L, Sartori MF, Albisetti W, Brini AT. Osteogenic
differentiation of human adipose-derived stem cells: comparison of
two different inductive media. J Tissue Eng Regen Med
2007;1(2):154–7.
[46] Maxson S, Burg KJL. Conditioned media cause increases in select
osteogenic and adipogenic differentiation markers in mesenchymal
stem cell cultures. J Tissue Eng Regen Med 2008;2(2–3):147–54.
[47] Mano JF, Korianova D, Reis RL. Thermal properties of thermoplastic starch/synthetic polymer blends with potential biomedical
applicability. J Mater Sci Mater Med 2003;14(2):127–35.
[48] Chasin M, Langer R, editorsBiodegradable polymers as drug delivery
systems. New York: Marcel Dekker; 1990. p. 1–42.
[49] Rodriguez M, Vila-Jato JL, Torres D. Design of a new multiparticulate system for potential site-specific and controlled drug delivery to
the colonic region. J Control Release 1998;55(1):67–77.
1045
[50] Crotts G, Park TG. Preparation of porous and nonporous biodegradable polymeric hollow microspheres. J Control Release
1995;35(2–3):91–105.
[51] Benoit MA, Baras B, Gillard J. Preparation and characterization of
protein-loaded poly(e-caprolactone) microparticles for oral vaccine
delivery. Int J Pharm 1999;184(1):73–84.
[52] Avérous L. Biodegradable multiphase systems based on plasticized
starch: a review. J Macromol Sci C – Polym Rev
2004;44(3):231–74.
[53] Elzein T, Nasser-Eddine M, Delaite C, Bistac S, Dumas P. FTIR
study of polycaprolactone chain organization at interfaces. J Colloids
Interfaces Sci 2004;273(2):381–7.
[54] Pashkuleva I, Marques AP, Vaz F, Reis RL. Surface modification of
starch based blends using potassium permanganate-nitric acid system
and its effect on the adhesion and proliferation of osteoblast-like cells.
J Mater Sci Mater Med 2005;16(1):81–92.
[55] Barikani M, Mohammadi M. Synthesis and characterization of
starch-modified polyurethane. Carbohydr Polym 2007;68:773–80.
[56] Igartua M, Hernandez RM, Esquisable A, Gascon AR, Calvo MB,
Pedraz JL. Influence of formulation variables on the in vitro release of
albumin from biodegradable microparticulate systems. J Microencapsul Micro Nano Carriers 1997;14(3):349–56.
[57] O’Hagan DT, Jeffery H, Davis SS. The preparation and characterization of poly(lactide-co-glycolide) microcapsules: III. Microparticle/
polymer degradation rates and the in vitro release of a model protein.
Int J Pharm 1994;103(1):37–45.
[58] Sah HK, Toddywala R, Chien YW. The influence of biodegradable
microcapsule formulations on the controlled release of a protein. J
Control Release 1994;30(3):201–11.
[59] Giunchedi P, Conti B, Maggi L, Conte U. Cellulose acetate
butyrate and polycaprolactone for ketoprofen spray-dried microsphere preparation. J Microencapsul Micro Nano Carriers
1994;11(4):381–93.
[60] Embleton JK, Tighe BJ. Polymers for biodegradable medical
devices. X. Microencapsulation studies: control of poly-hydroxybutyrate-hydroxyvalerate microcapsules porosity via polycaprolactone blending. J Microencapsul Micro Nano Carriers
1993;10(3):341–52.
[61] Yang Y-Y, Chung T-S, Ng NP. Morphology, drug distribution, and
in vitro release profiles of biodegradable polymeric microspheres
containing protein fabricated by double-emulsion solvent extraction/
evaporation method. Biomaterials 2001;22(3):231–41.
[62] Jameela SR, Suma N, Jayakrishnan A. Protein release from poly(ecaprolactone) microspheres prepared by melt encapsulation and
solvent evaporation techniques: a comparative study. J Biomater Sci
Polym Ed 1997;8(6):457–66.
[63] Silva GA, Ducheyne P, Reis RL. Materials in particulate form for
tissue engineering. 1. Basic concepts. J Tissue Eng Regen Med
2007;1(1):4–24.
[64] Yoon JJ, Kim JH, Park TG. Dexamethasone-releasing biodegradable
polymer scaffolds fabricated by a gas-foaming/salt-leaching method.
Biomaterials 2003;24(13):2323–9.
All in-text references underlined in blue are linked to publications on ResearchGate, letting you access and read them immediately.